Questions About Clinical Effect Highlight Advisory Committee Uncertainty Over Astellas’ Mirabegron
Reproductive health drugs advisory committee gives FDA a recommendation for approval for treatment of overactive bladder, but few answers to safety questions, and raises concerns about efficacy.
You may also be interested in...
Bipartisan Senate confirmation vote comes despite concerns about Stephen Hahn's non-answers to e-cigarette regulation questions.
Hoping to avoid litigation discovery, sponsors ask FDA for avenue to explain patent issues during labeling discussions without written record; negotiations for BsUFA III may be opportunity to create such a process.